Quantifying Artificial Pancreas-related Changes in Diabetic Neuropathy (QUANT-AP)
A longitudinal, single centre study to assess the effects of Artificial Pancreas-related Changes in Diabetic Neuropathy
- Hospital – Speciality: Manchester Royal Infirmary – Diabetes
- Study type: Observational
Summary
Patients with type 1 diabetes are prescribed multiple daily injections (MDI) of insulin to manage their glucose control. However, insulin pump therapy also known as continuous subcutaneous insulin infusion (CSII) and, more recently, the
Artificial Pancreas (AP) can be used as the insulin delivery method. Diabetes, Endocrine and Metabolism Centre in Manchester is the first adult diabetes centre in Europe to pioneer and use a commercially approved AP in clinical
practice.
AP has the advantage of being able to provide insulin at variable doses, which is closer to the natural process occurring within an individual without diabetes currently. It is considered to be the most physiological method of insulin
delivery and has been shown to improve glycaemic control, quality of life and reduce the risk of hypoglycaemia (low blood glucose level).
In this study we aim to investigate the effect of using AP on neuropathy. This will be in comparison to a control group of patients on MDI. We will use a variety of neuropathy measures and symptom questionnaires to assess structural and functional neuropathy status. We hypothesise that those patients receiving AP will demonstrate an improvement in symptoms and nerve regeneration.The findings would have a significant impact for patients as AP is already available on the NHS under certain considerations.
Participant group
Cases: Patients with type 1 diabetes aged 18-70 starting artificial pancreas (AP) therapy.
Controls: Patients with type 1 diabetes aged 18-70 on MDI therapy where there is no plan for moving to either insulin pump therapy or AP in the next 12 months.
Participant group
Individuals attending the diabetes centre at MFT will be introduced to the study by their direct care team.
Study open date and expected length
Opened: 23 January 2024
Expected end date: 01 June 2026
Results
Pending – this study is still active.
Contact details
Telephone number: 0161 276 6102
Email address: Shazli.azmi@mft.nhs.uk
- IRAS number: 319534
